Menu Search
Equities

Abbott Laboratories

ABT:SWX

Abbott Laboratories

Actions
Health CareMedical Equipment and Services
  • Price (CHF)93.50
  • Today's Change0.00 / 0.00%
  • Shares traded10.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 30 2024 08:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.

  • Revenue in USD (TTM)41.22bn
  • Net income in USD5.77bn
  • Incorporated1900
  • Employees114.00k
  • Location
    Abbott Laboratories100 Abbott Park Road, Abbot ParkABBOTT PARK 60064-3500United StatesUSA
  • Phone+1 (224) 667-6100
  • Websitehttps://www.abbott.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.